Meta-analysis of the efficacy and safety total glucosides of paeonia in the treatment of systemic lupus erythematosus
- VernacularTitle:白芍总苷制剂治疗系统性红斑狼疮有效性及安全性的Meta分析
- Author:
Xiangyan HAO
1
;
Jiahui LENG
2
;
Zhengqi LIU
2
;
Xinchang WANG
3
;
Cong HUANG
2
;
Xiaopeng LI
4
;
Yi LING
2
Author Information
1. Graduate School，Guizhou University of Traditional Chinese Medicine，Guiyang 550002，China
2. Dept. of Rheumatology and Immunology，the Second Affiliated Hospital of Guizhou University of TCM，Guiyang 550002，China
3. Dept. of Rheumatology and Immunology，the Second Affiliated Hospital of Zhejiang University of TCM，Hangzhou 310005，China
4. Scientific Research Department，the Second Affiliated Hospital of Zhejiang University of TCM，Hangzhou 310005，China
- Publication Type:Journal Article
- Keywords:
systemic lupus erythematosus;
total glucosides of paeonia;
meta-analysis;
efficacy;
safety
- From:
China Pharmacy
2026;37(2):232-237
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the efficacy and safety of total glucosides of paeonia （TGP） in the treatment of systemic lupus erythematosus （SLE）. METHODS Randomized controlled trial （RCT） about TGP combined with western medicine versus western medicine alone for SLE treatment were retrieved from PubMed， Embase， Cochrane Library， Web of Science， CNKI， VIP， Wanfang Data， and CBM. The search period spanned from the inception of each database to June 1， 2025. After literature screening， data extraction， and quality assessment of the included studies， Meta-analysis was performed using RevMan 5.4 software. RESULTS Fifteen RCTs， involving 1 318 patients， were included. Meta-analysis results showed that compared with western medicine alone， TGP combined with western medicine significantly improved clinical efficacy [OR＝4.96， 95%CI（3.41， 7.23）， P＜0.000 01]， complement 3 [MD＝0.18， 95%CI （0.13， 0.23）， P＜0.000 01] and complement 4[MD＝0.08， 般021） 95%CI （0.04， 0.11）， P＜0.000 01]， and reduced the levels of immunoglobulin G （IgG） [MD＝－3.10， 95%CI （－3.59，－2.62）， P＜0.000 01]， IgA [MD＝－0.68， 95%CI （－0.78， －0.58）， P＜0.000 01]， IgM [MD＝－0.43， 95%CI （－0.53，－0.34）， P＜0.000 01]， systemic lupus erythematosus disease activity index （SLEDAI） [MD＝－1.59， 95%CI （－2.20， －0.99）， P＜0.000 01]， recurrence rate [OR＝0.23， 95%CI （0.13， 0.42）， P＜0.000 01] and the incidence of adverse drug reactions [OR＝ 0.54， 95%CI （0.36， 0.82）， P＝0.004]. CONCLUSIONS TGP therapy can improve clinical efficacy of SLE patients， promote the restoration of immunoglobulins and complements， reduce SLEDAI and recurrence rate and has good safety.
